Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 3/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.58 |
| ▸ | ITGB2 | P05107 | 9/20 | 0.40 |
| ▸ | ICAM1 | P05362 | 9/20 | 0.40 |
| ▸ | ITGAL | P20701 | 9/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | CCR2 | P41597 | 3/20 | 0.37 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4575696 | 0.82 | PTGS1 (0.56) | PTGS1PTGS2ITGB2ICAM1ITGAL | |
| SCHEMBL9538398 | 0.81 | PTGS1 (0.55) | PTGS1PTGS2ITGB2ICAM1ITGAL | |
| SCHEMBL9539406 | 0.80 | PTGS1 (0.54) | PTGS1PTGS2ITGB2ICAM1ITGAL | |
| SCHEMBL7979738 | 0.75 | PTGS2 (0.56) | PTGS1PTGS2ITGB2ICAM1ITGAL | |
| SCHEMBL7066853 | 0.75 | PTGS2 (0.53) | PTGS1PTGS2ITGB2ICAM1ITGAL | |
| SCHEMBL14906059 | 0.75 | MCL1 (0.61) | PTGS1PTGS2MAPTHPGDTSHR | |
| SCHEMBL11560825 | 0.73 | MCL1 (0.59) | PTGS1PTGS2MAPTHPGDTSHR | |
| SCHEMBL7063649 | 0.73 | PTGS1 (0.48) | PTGS1PTGS2ITGB2ICAM1ITGAL | |
| SCHEMBL7067165 | 0.72 | PTGS1 (0.53) | PTGS1PTGS2MEN1ALDH1A1KMT2A | |
| SCHEMBL8098762 | 0.72 | PTGS1 (0.45) | PTGS1PTGS2ALDH1A1HPGDCCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1414526-A2 | ANTIANGIOGENIC COMBINATION THERAPY FOR THE TREATMENT OF CANCER | Pharmacia Corporation (US) | 2004-05-06 | — | — | EP | claimed |
| WO-2002085459-A2 | ANTIANGIOGENIC COMBINATION THERAPY FOR THE TREATMENT OF CANCER | PHARMACIA CORPORATION (US) | 2002-10-31 | — | — | WO | claimed |
| EP-1303308-A2 | ALDOSTERONE ANTAGONIST AND CYCLOOXYGENASE-2 INHIBITOR COMBINATION THERAPY TO PREVENT OR TREAT INFLAMMATION-RELATED CARDIOVASCULAR DISORDERS | Pharmacia Corporation (US) | 2003-04-23 | — | — | EP | disclosed |
| WO-2002009759-A2 | ALDOSTERONE ANTAGONIST AND CYCLOOXYGENASE-2 INHIBITOR COMBINATION THERAPY TO PREVENT OR TREAT INFLAMMATION-RELATED CARDIOVASCULAR DISORDERS | PHARMACIA CORPORATION (US) | 2002-02-07 | — | — | WO | disclosed |